Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-603 in HER2-positive solid tumors
NCT04650451Phase 1Suspended
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bpx-603 in solid tumor, sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoints: Proportion of subjects experiencing Dose Limiting Toxicities at 35 days and Maximum tolerated dose and/or recommended dose for expansion at 2 years. Started Dec 2020; status: suspended.
02
Drugs
bpx-603
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04650451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650451.